BTIG Research Cuts Xtant Medical (NYSEAMERICAN:XTNT) Price Target to $1.00

Xtant Medical (NYSEAMERICAN:XTNT) had its price target reduced by BTIG Research from $1.50 to $1.00 in a report released on Tuesday,Benzinga reports. They currently have a buy rating on the medical device company’s stock.

Separately, Craig Hallum reissued a “buy” rating on shares of Xtant Medical in a report on Wednesday, March 18th. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $1.00.

Xtant Medical Stock Down 7.5%

XTNT stock opened at $0.49 on Tuesday. Xtant Medical has a fifty-two week low of $0.34 and a fifty-two week high of $0.95. The business’s 50-day moving average is $0.59 and its two-hundred day moving average is $0.67. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.06 and a current ratio of 2.21. The company has a market cap of $68.93 million, a price-to-earnings ratio of 16.41 and a beta of -0.16.

Xtant Medical (NYSEAMERICAN:XTNT) last released its quarterly earnings results on Tuesday, March 31st. The medical device company reported $0.03 earnings per share (EPS) for the quarter. The business had revenue of $32.36 million during the quarter, compared to the consensus estimate of $30.75 million. Xtant Medical had a return on equity of 3.77% and a net margin of 1.32%.

Hedge Funds Weigh In On Xtant Medical

Several institutional investors and hedge funds have recently bought and sold shares of XTNT. AWM Investment Company Inc. purchased a new stake in Xtant Medical in the second quarter worth about $4,875,000. Crescent Grove Advisors LLC lifted its position in shares of Xtant Medical by 94.3% during the 2nd quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company’s stock valued at $304,000 after buying an additional 200,000 shares in the last quarter. Wiregrass Investment Management LLC purchased a new position in shares of Xtant Medical during the 4th quarter valued at about $81,000. Renaissance Technologies LLC grew its stake in shares of Xtant Medical by 28.8% during the 4th quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock valued at $721,000 after acquiring an additional 205,945 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of Xtant Medical by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock valued at $1,529,000 after acquiring an additional 104,159 shares during the period. 69.33% of the stock is currently owned by hedge funds and other institutional investors.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.